Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast Carcinoma.
作者信息
Shukla Neerav, Roberts Stephen S, Baki Mollah O, Mushtaq Qazi, Goss Paul E, Park Ben H, Gundem Gunes, Tian Ken, Geiger Heather, Redfield Kristie, Behr Gerald, Benayed Ryma, Zehir Ahmet, Hechtman Jaclyn F, Darnell Robert B, Papaemmanuil Elli, Ladanyi Marc, Ku Nora, Kung Andrew L, Baselga José, Drilon Alexander, Hyman David M
机构信息
Department of Pediatrics, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.
Professor Dr. Obayedullah Ferdousi Foundation Cancer Hospital and Research Institute.
出版信息
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00034. Epub 2017 Aug 18.
Abstract
摘要
相似文献
1
Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast Carcinoma.难治性小儿融合阳性分泌性乳腺癌的成功靶向治疗
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00034. Epub 2017 Aug 18.
2
Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion.涎腺乳腺样分泌癌：一项临床病理及分子研究，包括2例携带ETV6-X融合基因的病例
Am J Surg Pathol. 2015 May;39(5):602-10. doi: 10.1097/PAS.0000000000000392.
3
ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual.一名男变女变性者乳腺分泌性癌中的ETV6-NTRK3基因融合
Breast. 2005 Feb;14(1):71-4. doi: 10.1016/j.breast.2004.04.005.
4
Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.分泌性乳腺癌：一种以特异性ETV6-NTRK3基因融合为特征的组织病理学和基因组谱。
Am J Surg Pathol. 2015 Nov;39(11):1458-67. doi: 10.1097/PAS.0000000000000487.
5
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.分泌型乳腺癌中ETV6-NTRK3融合基因的荧光原位杂交研究
Genes Chromosomes Cancer. 2004 Jun;40(2):152-7. doi: 10.1002/gcc.20028.
6
Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.涎腺乳腺样分泌性癌：25例ETV6基因重排肿瘤的分子分析，标准逆转录聚合酶链反应未检测到经典ETV6-NTRK3融合转录本：4例携带ETV6-X基因融合病例报告
Am J Surg Pathol. 2016 Jan;40(1):3-13. doi: 10.1097/PAS.0000000000000537.
7
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.婴儿复发性、化疗耐药性婴儿纤维肉瘤携带特征性 ETV6-NTRK3 基因融合，对 TRK 抑制剂拉罗替尼快速、完全和持续的肿瘤反应。
Ann Oncol. 2019 Nov;30 Suppl 8:viii31-viii35. doi: 10.1093/annonc/mdz382. Epub 2019 Dec 24.
8
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.婴儿复发性、化疗耐药性婴儿纤维肉瘤携带特征性 ETV6-NTRK3 基因融合，对 TRK 抑制剂拉罗替尼快速、完全和持续的肿瘤应答。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii31-viii35. doi: 10.1093/annonc/mdz382.
9
Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.唾液腺癌中的新型基因融合：扩大 ETV6 家族。
Hum Pathol. 2019 Jan;83:50-58. doi: 10.1016/j.humpath.2018.08.011. Epub 2018 Aug 18.
10
Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.31 例 ETV6-NTRK3 融合基因阳性（乳腺型）涎腺分泌型癌患者的临床病理特征和预后分析。
Oral Oncol. 2018 Jul;82:29-33. doi: 10.1016/j.oraloncology.2018.04.022. Epub 2018 May 11.
引用本文的文献
1
Genomic Predictive Biomarkers in Breast Cancer: The and .乳腺癌中的基因组预测生物标志物：以及。 （你提供的原文似乎不完整，翻译可能不太准确，你可补充完整原文后再让我翻译）
Int J Mol Sci. 2025 Jul 28;26(15):7300. doi: 10.3390/ijms26157300.
2
A rare ER-positive secretory breast carcinoma: diagnostic challenges and surgical treatment.一例罕见的雌激素受体阳性分泌性乳腺癌：诊断挑战与外科治疗
Ann Med Surg (Lond). 2025 Jun 23;87(8):5257-5260. doi: 10.1097/MS9.0000000000003490. eCollection 2025 Aug.
3
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.解析罕见乳腺癌亚型的复杂性并把握机遇。
NPJ Breast Cancer. 2025 Jan 24;11(1):6. doi: 10.1038/s41523-025-00719-w.
4
Secretory Carcinoma of the Breast with Apocrine Differentiation-A Peculiar Entity.乳腺伴大汗腺分化的分泌癌——一种特殊的实体。
Medicina (Kaunas). 2024 Jun 1;60(6):924. doi: 10.3390/medicina60060924.
5
Drug repositioning in thyroid cancer: from point mutations to gene fusions.甲状腺癌中的药物重新定位：从点突变到基因融合
Front Oncol. 2024 May 8;14:1407511. doi: 10.3389/fonc.2024.1407511. eCollection 2024.
6
Narrative review of progress in pathological diagnosis of breast cancer.乳腺癌病理诊断进展的叙述性综述
Transl Breast Cancer Res. 2022 Apr 30;3:16. doi: 10.21037/tbcr-22-11. eCollection 2022.
7
Defining the clinical characteristics of mammary analog secretory carcinoma of the salivary gland: Analysis of the National Cancer Database.确定涎腺乳腺样分泌癌的临床特征：国家癌症数据库分析
SAGE Open Med. 2023 Sep 25;11:20503121231200103. doi: 10.1177/20503121231200103. eCollection 2023.
8
Rare subtypes of triple negative breast cancer: Current understanding and future directions.三阴性乳腺癌的罕见亚型：当前认识与未来方向。
NPJ Breast Cancer. 2023 Jun 23;9(1):55. doi: 10.1038/s41523-023-00554-x.
9
Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features.一组分泌性乳腺癌的临床病理特征和基因组特征，其中进展病例具有更复杂的基因组特征。
Diagn Pathol. 2022 Dec 31;17(1):101. doi: 10.1186/s13000-022-01284-7.
10
Advancement of secretory breast carcinoma: a narrative review.分泌性乳腺癌的进展：一篇叙述性综述。
Ann Transl Med. 2022 Nov;10(21):1178. doi: 10.21037/atm-22-2491.
本文引用的文献
1
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.从10000例患者的前瞻性临床测序中揭示的转移性癌症的突变图谱。
Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8.
2
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.560例乳腺癌全基因组序列中的体细胞突变图谱。
Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.
3
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.采用原肌球蛋白相关激酶抑制剂LOXO-101成功治疗的伴有NTRK3-ETV6融合的婴儿纤维肉瘤
Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. doi: 10.1002/pbc.26026. Epub 2016 Apr 19.
4
DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution.DeconstructSigs：剖析单个肿瘤中的突变过程可区分DNA修复缺陷和癌演变模式。
Genome Biol. 2016 Feb 22;17:31. doi: 10.1186/s13059-016-0893-4.
5
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).乳腺类似物分泌癌（MASC）中ETV6-NTRK3基因被鉴定后，MASC背后隐藏着什么：恩曲替尼的临床反应和获得性耐药。
Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15.
6
cgpPindel: Identifying Somatically Acquired Insertion and Deletion Events from Paired End Sequencing.cgpPindel：从双末端测序中识别体细胞获得的插入和缺失事件
Curr Protoc Bioinformatics. 2015 Dec 17;52:15.7.1-15.7.12. doi: 10.1002/0471250953.bi1507s52.
7
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.一名软组织肉瘤患者中存在致癌性NTRK融合，对原肌球蛋白相关激酶抑制剂LOXO-101有反应。
Cancer Discov. 2015 Oct;5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27.
8
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.纪念斯隆凯特琳癌症中心可操作癌症靶点综合突变分析（MSK-IMPACT）：一种基于杂交捕获的实体瘤分子肿瘤学新一代测序临床检测方法。
J Mol Diagn. 2015 May;17(3):251-64. doi: 10.1016/j.jmoldx.2014.12.006. Epub 2015 Mar 20.
9
TRKing down an old oncogene in a new era of targeted therapy.在靶向治疗的新时代追踪一个古老的癌基因。
Cancer Discov. 2015 Jan;5(1):25-34. doi: 10.1158/2159-8290.CD-14-0765. Epub 2014 Dec 19.
10
Anchored multiplex PCR for targeted next-generation sequencing.靶向下一代测序的锚定多重 PCR。
Nat Med. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10.
Zotero 插件